Methods
treatment-refractory, colorectal cancer, death, Cancer
COLORECTAL CANCER, CANCER
The Canadian Cancer Trials Group (CCTG) CO.26 study is a phase 2 study that randomized 180 patients with treatment-refractory advanced colorectal cancer unselected for MSI status to durvalumab, an antibody against programmed death ligand 1, plus tremelimumab, an antibody against the cytotoxic T-cell lymphocyte antigen-4 or best supportive care (BSC) in a 2:1 fashion between August 10, 2016, and June 15, 2017.